Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Bevacizumab 234Fluorouracil 220Oxaliplatin 216Irinotecan 215Leucovorin 199Capecitabine 153Cetuximab 146Panitumumab 70Folfox protocol 51regorafenib 43Radiotherapy 38pembrolizumab 37IFL protocol 36HMPL-013 36trifluridine tipiracil drug combination 32Nivolumab 32Drug Therapy 26Neoadjuvant Therapy 24Trifluridine 18Celecoxib 18tislelizumab 17XELOX 17sintilimab 16Trastuzumab 16durvalumab 15atezolizumab 15aflibercept 15Chemotherapy, Adjuvant 15Biopsy 15apatinib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Colorectal Neoplasms × pidilizumab × Clear all
NCT00890305 2015-07-08

Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone

Medivation, Inc.

Phase 2 Completed
171 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡